FORECAST OF THE INTRAVENOUS & SUBCUTANEOUS
IMMUNE GLOBULIN (IVIG/SCIG) MARKET IN
THE UNITED STATES BETWEEN 2012 AND 2017

 

Three years ago, the Marketing Research Bureau published a report titled A Forecast of the IVIG Market in the United States in 2015. Since that time, new intravenous and subcutaneous immunoglobulin preparations have been introduced, the industry has consolidated further, the demand for these products has continued to grow while payment for IVIG/SCIG treatment has become increasingly challenging. More than ever, IVIG, and now IVIG+SCIG became the undisputable driver of the plasma proteins market.

The early results of a clinical trial for the treatment of Alzheimer’s disease suggest that the demand for IVIG may increase significantly if and when this indication is approved for marketing in two to four years. At the same time, the growing demand for IVIG in emerging markets contributes to the market expansion, putting further pressure on production.

This new report describes the 2011 IVIG/SCIG market in the U.S. and forecasts the demand to 2017 in units and dollars, based on the main medical conditions for which these products are prescribed. Three scenarios, optimistic, likely and pessimistic have been developed. The forecasts take into account a possible approval of IVIG for Alzheimer’s disease treatment in three or four years, as well as the SCIG segment of the polyvalent immunoglobulin market. The report’s price and table of contents are available upon request.